SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (154372)3/3/2002 1:52:13 PM
From: reaper  Read Replies (2) | Respond to of 436258
 
but one would think that some significant portion of the SEPR market cap is based upon approval for the drug (especially since we can all see the excellent-looking abstracts). so if for some reason it doesn't get approved, the stock will do seriously not well.

i likely could have chosen my words a little better (the "make-or-break" reference) as yes, SEPR will not instantly go out of business if Soltara gets turned down. but the stock will take a large hit.

am i correct in my expectations for a 9 March timeline on FDA action??

Cheers



To: Harold Engstrom who wrote (154372)3/7/2002 8:44:58 AM
From: reaper  Read Replies (5) | Respond to of 436258
 
looks like SEPR turned down

Sepracor is Notified of Not-Approvable Action for SOLTARA(TM) Brand Tecastemizole
biz.yahoo.com
{actually, on a closer read it just looks like maybe a year delay. its "not approvABLE" which is different than "not appovED"

that said, likely gonna be a good day even if the Dow goes up 300 <g>

Message 17045213


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News